TAVI and SAVR Almost Equally Performed in California Patients Under 60

A recent study by Jad Malas et al. comparing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) in patients less than 60 years of age was presented during the 2024 STS Annual Meeting in San Antonio, Texas. The analysis included data from 2,306 patients less than 60 years old who underwent TAVI or bioprosthetic SAVR between 2013 and 2021 in California, USA. The data originated from the California State Discharge Administrative Database. Almost half of patients less than 60 years old treated for aortic stenosis in California between 2013 and 2021 received TAVI instead of SAVR, with a steady increase in TAVI use for this population over the study period. The annual increase in TAVI use was about five percent. However, the study also showed a 2.5-fold increased risk of death at five years with TAVI compared to SAVR.